Hot‐topic debate on kidney function: Renal‐sparing approaches are beneficial

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Liver transplantation

• Publication date

  2011-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/lt.22392PMID 21796759
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Reduced‐Dose Tacrolimus with Mycophenolate Mofetil vs. Standard‐Dose Tacrolimus in Liver Transplantation: A Randomized Study

  2011cited by this paper
• Long‐term, maintenance MMF monotherapy improves the fibrosis progression in liver transplant recipients with recurrent hepatitis C

  2011cited by this paper
• Challenges in diagnosing acute calcineurin-inhibitor induced nephrotoxicity: from toxicogenomics to emerging biomarkers.

  2011cited by this paper
• Immunosuppression in liver transplant recipients with renal impairment.

  2011cited by this paper
• Serum sodium, renal function, and survival of patients with end-stage liver disease.

  2010influential reference
• The immunosuppressive pipeline: Meeting unmet needs in liver transplantation

  2010cited by this paper
• Inaccuracies of creatinine and creatinine‐based equations in candidates for liver transplantation with low creatinine: Impact on the model for end‐stage liver disease score

  2010cited by this paper
• A Phase III Study of Belatacept‐based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study)

  2010cited by this paper
• The spectrum of renal lesions in patients with cirrhosis: a clinicopathological study

  2010cited by this paper
• Mycophenolate Mofetil Monotherapy for Severe Side Effects of Calcineurin Inhibitors Following Liver Transplantation

  2009cited by this paper
• Delayed Introduction of Reduced‐Dose Tacrolimus, and Renal Function in Liver Transplantation: The ‘ReSpECT' Study

  2009cited by this paper
• Two yr mycophenolate mofetil plus low‐dose calcineurin inhibitor for renal dysfunction after liver transplant

  2009cited by this paper
• Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction

  2009cited by this paper
• Impact of Reduced Nephron Mass on Cyclosporine- and/or Sirolimus-Induced Nephrotoxicity

  2009cited by this paper
• Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low‐dose calcineurin inhibitor regimens

  2008cited by this paper
• Switch to 1.5 grams MMF monotherapy for CNI‐related toxicity in liver transplantation is safe and improves renal function, dyslipidemia, and hypertension

  2007cited by this paper
• Hepatorenal syndrome: A proposal for kidney after liver transplantation (KALT)

  2007cited by this paper
• Clinical trial: switch to combined mycophenolate mofetil and minimal dose calcineurin inhibitor in stable liver transplant patients – assessment of renal and allograft function, cardiovascular risk factors and immune monitoring

  2007influential reference
• Impact of implementation of the MELD scoring system on the prevalence and incidence of chronic renal disease following liver transplantation

  2006cited by this paper
• Chronic kidney disease post-liver transplantation.

  2006cited by this paper
• Impact of implementation of the MELD scoring system on the prevalence and incidence of chronic renal disease following liver transplantation

  2006cited by this paper
• The course of type 1 hepato-renal syndrome post liver transplantation.

  2006cited by this paper
• Sirolimus early graft nephrotoxicity: clinical and experimental data.

  2006cited by this paper
• Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation

  2006cited by this paper
• Continued Influence of Preoperative Renal Function on Outcome of Orthotopic Liver Transplant (OLTX) in the US: Where Will MELD Lead Us?

  2006cited by this paper
• ACE Gene D/D Genotype as a Risk Factor for Chronic Nephrotoxicity from Calcineurin Inhibitors in Liver Transplant Recipients

  2006cited by this paper
• Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low‐dose tacrolimus regimen vs. a standard‐dose tacrolimus and mycophenolate mofetil regimen: A multicenter randomized clinical trial

  2005cited by this paper
• Renal Histopathological Lesions After Orthotopic Liver Transplantation (OLT)

  2005cited by this paper
• Mycophenolate Mofetil for Renal Dysfunction in Liver Transplant Recipients on Cyclosporine or Tacrolimus: Randomized, Prospective, Multicenter Pilot Study Results

  2005cited by this paper
• Superior Outcomes in Renal Transplantation after Early Cyclosporine Withdrawal and Sirolimus Maintenance Therapy, Regardless of Baseline Renal Function

  2005cited by this paper
• Mycophenolate Mofetil Can Be Used as Monotherapy Late After Liver Transplantation

  2004cited by this paper
• Independent risk factors and natural history of renal dysfunction in liver transplant recipients

  2003cited by this paper
• Acute renal failure in patients with cirrhosis: Perspectives in the age of MELD

  2003cited by this paper
• Chronic renal failure after transplantation of a nonrenal organ.

  2003influential reference
• Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial.

  2002cited by this paper
• K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

  2002cited by this paper
• Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations.

  2001cited by this paper
• Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study.

  2001cited by this paper

• Post–Liver Transplant Acute Kidney Injury

  2021cites this paper
• Efficacy and Safety of Delayed Prolonged-Release Tacrolimus Initiation in De Novo Hepatitis C Virus-Negative Orthotopic Liver Transplant Recipients: A Single-Center, Single-Arm, Prospective Study

  2019cites this paper
• Acute Kidney Injury After Liver Transplantation

  2018cites this paper
• Pretransplant renal function according to CKD‐EPI cystatin C equation is a prognostic factor of death after liver transplantation

  2016cites this paper
• Efficacy and Safety of Monotherapy With Mycophenolate Mofetil in Liver Transplantation Patients With Nephrotoxicity.

  2016cites this paper
• Management of renal failure in end‐stage liver disease: A critical appraisal

  2016cites this paper
• The Effect of Mammalian Target of Rapamycin Versus Calcineurin Inhibitor–based Immunosuppression on Measured Versus Estimated Glomerular Filtration Rate After Orthotopic Liver Transplantation

  2015cites this paper
• Traitement et suivi post-greffe

  2013cites this paper
• Current World Literature

  2012cites this paper
• Rabbit anti‐thymocyte globulin in liver transplantation: All that glitters is not gold, but 1000 patients are so many to dazzle

  2012cites this paper
• to optimize

  2012cites this paper